Morton Collins, INO board member, is certainly over-weighted.
The CEO and David B. Weiner are the two largest share holders.
"We" understand your confidence. LOL! I'll drink to that!
INO shareholders are betting on the next catalyst to be an announcement of an additional partnership. The "tell" given by the CEO was when he said they are in "deep discussions" mentioned in one of his event webcasts recently.
Also, note the pipeline as graphically illustrated in green, on their website. These are trials reserved for big pharma to partner with Inovio. The list of trials are growing, and involve the hardest to treat diseases. Eventually they will fill these trials with big pharma partners. Those listed in blue are owned by Inovio and will be taken to the goal line without partners.
The partnership made with Roche is a big validation point: Prostate cancer and Hepatitis b are now sponsored by Roche. The partner money is helpful for further funding Inovio's studies and operations.
Look for webcasts on Inovio's website for more info.
Good luck to all.
The CEO said that Inovio will be as big as Amgen.
He also said 2014 will "dwarf" 2013. I believe him.
Further validation -- Roche sponsoring the prostate cancer trials and Hepatitis b trials --10 million dollars up front payment, with milestone payments up to 422 million dollars.
2014 -- Expect more partnerships from other majors.
Cash runway into first qtr of 2016.
The shorts in the mean time will take every advantage to beat the stock up in periods of no news and spread fear and doubt. You can see the strong support at around the 2.00 mark.
Achieving best in class outcomes.
Good peer reviews.
CEO is winning awards.
This is the future of medicine in my opinion, using the bodies own immune system via synthetic DNA vaccines to fight disease.
By the way U of Penn team under David Porter and Carl June, and Juno Thereapeutics cured a 14 year old boy of Leukemia using re-engineered t-cells.
Inovio will shine too.
Microwishin, the trial you refer to is for Cervical Dysplasia. The beauty of Inovio's approach is to awaken the patients own immune system's t-cells to recognize and attack the cancer cells. The secret sauce, synthetic DNA plasmids (this method of creating plasmids involves a computer program to derive a synthetic consensus of the best gene sequences of the target, taking the best parts of it and making the synthetic plasmid. To make the plasmid, an ecoli bacteria without the chromosomes is used, then the synthetic DNA is added to it. The plasmids are made in pure water. No refrigeration concerns. These plasmids are then injected invivo by electroporation into the patient. Inovio holds over 400 patents, which includes the computer programs to design the synthetic DNA plasmids, and the Cellectra Electroporation device. By the way human DNA cannot be patented. Only synthetic DNA. This is a big plus for Inovio. The problem with cancer is, sometimes the t-cells ignore the cancer. Inovio's synthetic DNA awaken the t-cells to go after the cancer.
Dr. Kim, Phd, CEO, is so confident, he has already begun planning for phase 3.
Dr. Kim's mentor is David B. Weiner, PhD., U of Penn. is the father of synthetic DNA
Morton Collins, Inovio board member, has purchased shares on Nov 13. almost .5 million dollars worth.
Phil Greenberg, Phd, U of Wash., is science advisor for Inovio. He is considered the father of t-cells. Greenberg is also on the board for Juno Therapeutics. A 120 million dollar venture start up, Dr. Renier Brentjens, the CEO of Juno, gave a grand rounds talk where I work, I had to record his presentation, Sept 2013. 15 years ago he saw under the microscope what t-cells can do to cancer cells...gobble them up. Brentjens method is to engineer the t-cells directly, to go after the cancer cells. Inovio's method, is to awaken the t-cells with synthetic DNA plasmids to attack the cancer -not engineering the t-cells. Go to INO website for more info.
Captain, what was it like to fly the 747 the first time you flew it? I suppose the runways seem mighty narrow.
Dot connections...Juno Therapeutics (Dr. R. Brentjen) in collaboration with Univ of Penn
Phill Greenberg on Juno board and Inovio board.
We as investors in Inovio need to know if there is a collaboration or competition between Inovio's treatment strategy and the treatment strategy involving engineering t-cells. Conversely, if there is a combination treatment therapy that can use Inovio's Synthetic DNA with engineered t-cells to treat patients who did not have remission in the study mentiobned? Inquiring minds would like to know.
Note: This is not an Inovio treatment plan in this case, but in this treatment they are engineering the T cells to go after the target.
I think we talked about this previously here. There is a new video. We do know this is the same institution of Dr. Weiner and Dr. Kim.
Killing cancer like the common cold
By Elizabeth Cohen, Senior Medical Correspondent
updated 10:08 AM EST, Sat December 7, 2013
"This is absolutely one of the more exciting advances I've seen in cancer therapy in the last 20 years," said Dr. David Porter, a hematologist and oncologist at Penn. "We've entered into a whole new realm of medicine."
"The genetically modified T-cells have survived," Porter said. "They're still present and functional and have the ability to protect against recurrence."
A little off topic,
Bing this: Genomic Biomarker Discovery: Bringing the Genome to Life
Although this is not my field, I get the sense this area of science relates to Inovio somewhat.
The first step in patient care is to identify if the patient has the disease in question, biomarkers help answer the question with a test for a specific trait. "biomarker".
Pharmaceutical companies strategy: Find the right biomarker for a particular disease, make testing kits and sell them by the millions to the concerned public, cash the checks.
Investor opportunity: Find companies developing biomarker kits.
Question, how big is this market segment?
Anyone still a fence sitter about Inovio, please read this thread. Being an Inovio shareholder, you should feel you are well positioned for helping yourself to wealth creation and helping humanity to eventually obtain cures for what are considered the most impossible diseases. Utilizing an extensive patent portfolio of new and novel approaches to synthetic DNA vaccines and therapies, there is no other company like this. I can't name one in synthetic DNA, help out here if there is.
We have many reasons to be positive about Inovio's value proposition. Now is the time to buy before Inovio becomes a household name.
I really like the idea of creating many pipeline opportunities, keeping some of them, 100% ownership, and also farming out some of them in partnerships. Essentially, Inovio could become the bank and banker of DNA treatments and vaccines, offering opportunities to the tier one companies. Inovio will be selling the picks and shovels to the miners in a new gold rush. Inovio owns the mine and the future.